Fiera Capital Corp grew its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 38,066 shares of the company’s stock after purchasing an additional 3,001 shares during the quarter. Fiera Capital Corp’s holdings in Cencora were worth $12,857,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in COR. United Bank boosted its stake in shares of Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after purchasing an additional 305 shares during the period. Nebula Research & Development LLC purchased a new stake in Cencora in the second quarter worth $595,000. Treasurer of the State of North Carolina lifted its stake in Cencora by 7.9% in the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after acquiring an additional 6,244 shares during the period. Diversify Advisory Services LLC increased its position in Cencora by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after purchasing an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after purchasing an additional 15,154 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Cencora Price Performance
COR opened at $274.04 on Tuesday. The stock has a fifty day simple moving average of $291.82 and a two-hundred day simple moving average of $329.69. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The company has a market cap of $53.32 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 1.48 and a beta of 0.59. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.
Cencora Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.
Cencora declared that its board has initiated a share repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Robert W. Baird dropped their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Evercore set a $360.00 target price on shares of Cencora in a research report on Wednesday, April 8th. UBS Group raised their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Barclays raised their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Finally, William Blair assumed coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $380.25.
Check Out Our Latest Stock Report on Cencora
Cencora Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles
- Five stocks we like better than Cencora
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
